Loading clinical trials...
Loading clinical trials...
ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis.
Conditions
Interventions
Fitusiran
BPA prophylaxis
+1 more
Locations
35
United States
Investigational Site Number 0139
Los Angeles, California, United States
Investigational Site Number 6104
Prahran, Australia
Investigational Site Number 8604
Beijing, China
Investigational Site Number 4501
Copenhagen, Denmark
Investigational Site Number 3303
Lyon, France
Investigational Site Number 5301
Crumlin, Ireland
Start Date
July 25, 2018
Primary Completion Date
January 20, 2022
Completion Date
March 25, 2022
Last Updated
February 6, 2023
NCT03961243
NCT06820515
NCT05500807
NCT07101926
NCT06379789
NCT07226206
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions